DAX24.374 -0,2%Est505.648 ±0,0%MSCI World4.350 +0,5%Top 10 Crypto16,65 +1,1%Nas22.877 +0,1%Bitcoin102.881 +0,1%Euro1,1736 +0,1%Öl64,60 +0,4%Gold3.879 +0,6%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
DroneShield A2DMAA Rheinmetall 703000 NVIDIA 918422 RENK RENK73 Tesla A1CX3T HENSOLDT HAG000 Siemens Energy ENER6Y Plug Power A1JA81 Novo Nordisk A3EU6F Alibaba A117ME thyssenkrupp 750000 BASF BASF11 Lufthansa 823212 Deutsche Telekom 555750 D-Wave Quantum A3DSV9
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX fällt zurück -- US-Börsen höher -- BMW steigert US-Absatz deutlich -- Investoren wollen Billionen-Vergütung für Tesla-CEO Musk stoppen -- Palantir, Plug Power, IONOS, Boeing, Roche im Fokus
Top News
Rohstoffe im September 2025: So performten Goldpreis, Ölpreis und Co. Rohstoffe im September 2025: So performten Goldpreis, Ölpreis und Co.
Analysten sehen bei Deutsche Bank-Aktie Potenzial Analysten sehen bei Deutsche Bank-Aktie Potenzial
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Günstig global investieren mit unserem neuen FINANZEN.NET MSCI WORLD ETF - nur 0,12 % TER. Jetzt informieren!

Eli Lilly Aktie

Kaufen
Verkaufen
Eli Lilly Aktien-Sparplan
711,00 EUR +11,20 EUR +1,60 %
XETRA
840,60 USD +20,49 USD +2,50 %
BTT
Eli Lilly jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)
Smartphone

Marktkap.666,57 Mrd. EUR

KGV65,91Div. Rendite0,67%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN858560

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS5324571083

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolLLY

Eli Lilly Aktien News

DatumMeistgelesen
EN, Eli LillyLilly reports full Q4 2024 financial results and provides 2025 guidance
PR NewswireLilly reports full Q4 2024 financial results and provides 2025 guidance
PR NewswireLilly confirms date and conference call for fourth-quarter 2024 financial results and 2025 financial guidance announcement
EN, Eli LillyLilly confirms date and conference call for fourth-quarter 2024 financial results and 2025 financial guidance announcement
EN, Eli LillyFDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease
PR NewswireFDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease
PR NewswireLilly provides update on 2024 revenue guidance, announces 2025 revenue guidance
EN, Eli LillyLilly provides update on 2024 revenue guidance, announces 2025 revenue guidance
PR NewswireLilly to acquire Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program
EN, Eli LillyLilly to acquire Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program
PR NewswireLilly to participate in J.P. Morgan Healthcare Conference
EN, Eli LillyLilly to participate in J.P. Morgan Healthcare Conference
EN, Eli LillyLilly commends ITC ruling cracking down on the unlawful importation and sale of knock-off tirzepatide products that put Americans at risk
EN, Eli LillyFDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity
PR NewswireFDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity
PR NewswireLilly's Kisunla™ (donanemab-azbt) Approved in China for the Treatment of Early Symptomatic Alzheimer's Disease
EN, Eli LillyLilly's Kisunla™ (donanemab-azbt) Approved in China for the Treatment of Early Symptomatic Alzheimer's Disease
PR NewswireLilly and EVA Pharma announce regulatory approval and release of locally manufactured insulin in Egypt
EN, Eli LillyLilly and EVA Pharma announce regulatory approval and release of locally manufactured insulin in Egypt
PR NewswireLilly's Omvoh® (mirikizumab) recommended by CHMP for approval in the European Union for adults with moderately to severely active Crohn's disease
EN, Eli LillyLilly's Omvoh® (mirikizumab) recommended by CHMP for approval in the European Union for adults with moderately to severely active Crohn's disease
EN, Eli LillyLilly's Imlunestrant, an Oral SERD, Significantly Improved Progression-Free Survival as Monotherapy and in Combination with Verzenio® (abemaciclib) in Patients with ER+, HER2- Advanced Breast Cancer
PR NewswireLilly's Imlunestrant, an Oral SERD, Significantly Improved Progression-Free Survival as Monotherapy and in Combination with Verzenio® (abemaciclib) in Patients with ER+, HER2- Advanced Breast Cancer
EN, Eli LillyPhase 3 results for Lilly's Jaypirca® (pirtobrutinib) in covalent BTK inhibitor pre-treated chronic lymphocytic leukemia or small lymphocytic lymphoma to be presented at the 2024 ASH Annual Meeting
PR NewswirePhase 3 results for Lilly's Jaypirca® (pirtobrutinib) in covalent BTK inhibitor pre-treated chronic lymphocytic leukemia or small lymphocytic lymphoma to be presented at the 2024 ASH Annual Meeting
PR NewswireLilly announces new $15 billion share repurchase program and seventh consecutive 15% dividend increase
EN, Eli LillyLilly announces new $15 billion share repurchase program and seventh consecutive 15% dividend increase
PR NewswireCORE Kidney, Boehringer Ingelheim and Lilly Are Turning Up the Volume on Kidney Health at the 2025 Tournament of Roses® Parade
EN, Eli LillyCORE Kidney, Boehringer Ingelheim and Lilly Are Turning Up the Volume on Kidney Health at the 2025 Tournament of Roses® Parade
EN, Eli LillyLilly announces $3 billion expansion of its recently acquired manufacturing facility in Wisconsin
PR NewswireLilly announces $3 billion expansion of its recently acquired manufacturing facility in Wisconsin
EN, Eli LillyLilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%
PR NewswireLilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%
EN, Eli LillyLilly announces changes on board of directors
PR NewswireLilly announces changes on board of directors
EN, Eli LillyLilly's muvalaplin lowered lipoprotein(a) levels in adults with high risk for cardiovascular events by up to 85% at highest tested dose
PR NewswireLilly's muvalaplin lowered lipoprotein(a) levels in adults with high risk for cardiovascular events by up to 85% at highest tested dose
PR NewswireLilly's tirzepatide reduced the risk of worsening heart failure events by 38% in adults with heart failure with preserved ejection fraction (HFpEF) and obesity
EN, Eli LillyLilly's tirzepatide reduced the risk of worsening heart failure events by 38% in adults with heart failure with preserved ejection fraction (HFpEF) and obesity
EN, Eli LillyLilly Statement on New 340B Litigation

Eli Lilly News

Eli Lilly News: auf dieser Seite finden Sie alle Eli Lilly News und Nachrichten zur Eli Lilly Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Eli Lilly News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Eli Lilly News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.